Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - heparin sodium, quantity: 1000 iu/l - injection, solution - excipient ingredients: sodium chloride; citric acid monohydrate; dibasic sodium phosphate dodecahydrate; water for injections - indications as at 11 july 2003: heparin sodium in 0.9% sodium chloride intravenous infusion is indicated as an anticoagulant in extracorporeal circulation, dialysis procedures, and as an aid in the maintenance of catheter patency.

Spojené štáty - angličtina - NLM (National Library of Medicine)

fresenius kabi usa, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - citric acid 771.868 mg/g; heavy magnesium oxide 225.128 mg/g; sodium picosulfate 0.64 mg/g;   - powder for oral solution - 0.64 mg/g - active: citric acid 771.868 mg/g heavy magnesium oxide 225.128 mg/g sodium picosulfate 0.64 mg/g   excipient: aspartame

Nový Zéland - angličtina - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - citric acid 12.77 mg/g; macrogol 3350 755.68 mg/g (as macrogol 3350 prepared solution contains 6% w/w); potassium chloride 10.55 mg/g; sodium chloride 37.33 mg/g;  ; sodium sulfate 80.62 mg/g; citric acid 771.868 mg/g; heavy magnesium oxide 225.128 mg/g; sodium picosulfate 0.64 mg/g - combination - active: citric acid 12.77 mg/g macrogol 3350 755.68 mg/g (as macrogol 3350 prepared solution contains 6% w/w) potassium chloride 10.55 mg/g sodium chloride 37.33 mg/g   sodium sulfate 80.62 mg/g excipient: ascorbic acid aspartame lemon flavour ql58817 active: citric acid 771.868 mg/g heavy magnesium oxide 225.128 mg/g sodium picosulfate 0.64 mg/g excipient: aspartame - indicated for bowel emptying and cleansing by means of total gastrointestinal tract perfusion in preparation for gastrointestinal examination

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections; hydrochloric acid - ionolyte is indicated for:,- mild metabolic acidosis,- as a source of water and electrolytes

Austrália - angličtina - Department of Health (Therapeutic Goods Administration)

neolife international pty ltd - beta vulgaris, quantity: 10 mg; heavy magnesium oxide, quantity: 165.84 mg (equivalent: magnesium, qty 100 mg); magnesium citrate, quantity: 156.25 mg (equivalent: magnesium, qty 25 mg); raphanus sativus, quantity: 1 mg (equivalent: raphanus sativus, qty 2 mg); brassica oleracea var. viridis, quantity: 10 mg; brassica oleracea var. viridis, quantity: 2 mg (equivalent: brassica oleracea var. viridis, qty 4 mg); brassica oleracea var. italica, quantity: 2 mg (equivalent: brassica oleracea var. italica, qty 4 - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium carbonate; croscarmellose sodium; stearic acid; purified water; silicon dioxide; glycerol; hypromellose - maintain/support energy levels ; maintain/support general health and wellbeing ; maintain/support heart health ; maintain/support muscle health ; maintain/support muscle function

Spojené štáty - angličtina - NLM (National Library of Medicine)

medical purchasing solutions, llc - magnesium sulfate heptahydrate (unii: sk47b8698t) (magnesium cation - unii:t6v3lhy838) - magnesium sulfate injection, usp is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia.  in such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 meq/l) and the serum calcium level is normal (4.3 to 5.3 meq/l) or elevated. in total parenteral nutrition (tpn), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. magnesium sulfate injection is also indicated for the prevention and control of seizures in a pre-eclampsia and eclampsia, respectively. parenteral administration of the drug is contraindicated in patients with heart block or myocardial damage.

Izrael - angličtina - Ministry of Health

teva israel ltd - sodium chloride - solution for infusion - sodium chloride 0.45 %w/v - sodium chloride - supply of water and electrolytes

Spojené štáty - angličtina - NLM (National Library of Medicine)

bryant ranch prepack - sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - for once daily self-applied systemic use as a dental caries preventive in pediatric patients. it has been established that ingestion of fluoridated drinking water (1 ppm f¯) during the period of tooth development results in a significant decrease in the incidence of dental caries. sodium fluoride chewable tablets were developed to provide systemic fluoride for use as a supplement in pediatric patients from age 3 years to age 16 years and older living in areas where the drinking water fluoride contents does not exceed 0.6 ppm f¯. fluoride 1.0 mg tablets are contraindicated when the fluoride content of drinking water is >0.3 ppm f¯ and should not be administered to pediatric patients under 6 years. fluoride 0.5 mg tablets are contraindicated when the fluoride content of drinking water is more than 0.6 ppm f¯ and should not be administered to pediatric patients under age 6 when the fluoride content of drinking water is 0.3 ppm f¯ or more or to pediatric patients under age 3 years. fluoride 0.25 mg tablets are contraindicated when the fluoride content of drinking water is more than 0.6 ppm f¯ and should not be administered to pediatric patients under age 3 years when the fluoride content of drinking water is 0.3 ppm f¯ or more. do not administer sodium fluoride chewable tablets (any strength) to pediatric patients under age 3 years. sodium fluoride chewable tablets (any strength) are not indicated for use in adults.